Athenagen Initiates Phase II Clinical Trial in Alzheimer’s Disease
December 13, 2006
Read More...

Athenagen Expands Leadership Team with Two Seasoned Drug Development Professionals
October 23, 2006
Read More...

Athenagen Raises $50 Million in Series B Financing
September 28, 2006
Read More...

Athenagen Initiates Clinical Development of its Anti-angiogenic Eye Drop Therapy for AMD
August 21, 2006
Read More...

Athenagen Completes Merger with Zapaq - Union Creates Leading Neurovascular Disease Franchise
August 14, 2006
Read More...

Athenagen and Zapaq to Merge: Companies Combine Expertise, Create Leading Neuroscience Company
July 10, 2006
Read More...

Athenagen Announces Publication of Results from a Proof-of-Concept Trial
June 15, 2006
Read More...

Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
May 08, 2006
Read More...

Athenagen Acquires Osprey Pharmaceutical Company, Adds Clinical-Stage Alzheimer’s Drug Candidate
April 13, 2006
Read More...

Athenagen Adds A. Barr Dolan to its Board of Directors
February 22, 2006
Read More...